Baidu
map

硫胺素、维生素 C 和氢化可的松联合治疗脓毒症和感染性休克

2022-03-01 MedSci原创 MedSci原创

最近的一项研究表明,2017年全球估计有1100万例败血症相关死亡,占总死亡人数的19.7%。在脓毒症患者中经常检测到维生素C和硫胺素的缺乏,据报道,这归因于摄入量减少和代谢需求增加。

最近的一项研究表明,2017年全球估计有1100万例败血症相关死亡,占总死亡人数的19.7%。在脓毒症患者中经常检测到维生素C和硫胺素的缺乏,据报道,这归因于摄入量减少和代谢需求增加。

 

图1文章来源

该研究评估硫胺素和维生素C联合或不联合氢化可的松治疗脓毒症和感染性休克的临床疗效,共涉及8项RCT,共1428名患者。

结果显示,与安慰剂组相比,接受维生素C和硫胺素联合或不联合氢化可的松治疗的败血症和感染性休克患者的短期死亡率没有显着降低{风险比(RR),1.02[95%置信区间(CI)),0.87至1.20], p  =0.81, I 2  =0%; 风险差(RD),0[95%CI,-0.04至0.05]}。

图2脓毒症患者短期死亡率和 delta SOFA 的森林图,比较了维生素 C 和硫胺素联合或不联合氢化可的松与安慰剂的联合治疗。

然而,联合治疗与SOFA评分[平均差(MD),-0.63,(95%CI,-0.96to-0.29, p  <0.001, I 2  =0%]和血管加压药持续时间(MD,-22.11[95%CI,-30.46至-13.77],p  <0.001,I2  =6%)。

图3短期死亡率和 delta SOFA 的试验序贯分析比较了败血症患者中维生素 C 和硫胺素加或不加氢化可的松与安慰剂的联合治疗。蓝色z曲线是通过应用随机效应模型绘制的。SOFA序贯器官衰竭评估

此外,其他结果的汇总估计值没有统计学差异。

研究显示,与安慰剂相比,维生素C和硫胺素联合治疗(加或不加氢化可的松)对短期死亡率没有影响,但与脓毒症和感染性休克患者的SOFA评分显着降低有关。

原始文章:

Renqi Yao, Yibing Zhu, Yue Yu, Zhixuan Li, Lixue Wang, Liyu Zheng, Jingyan Li, Huibin Huang, Guosheng Wu, Feng Zhu, Zhaofan Xia, Chao Ren, Yongming Yao, Combination therapy of thiamine, vitamin C and hydrocortisone in treating patients with sepsis and septic shock: a meta-analysis and trial sequential analysis,Burns & Trauma, Volume 9, 2021, tkab040

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655527, encodeId=5d15165552e29, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 15 17:09:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198538, encodeId=6b2e1198538ae, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:22:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198537, encodeId=a310119853e1f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:21:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313855, encodeId=1b8b13138559a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417475, encodeId=7945141e475fd, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508489, encodeId=1366150848980, content=<a href='/topic/show?id=7217e356711' target=_blank style='color:#2F92EE;'>#硫胺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73567, encryptionId=7217e356711, topicName=硫胺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87989977401, createdName=sjq030, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655527, encodeId=5d15165552e29, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 15 17:09:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198538, encodeId=6b2e1198538ae, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:22:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198537, encodeId=a310119853e1f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:21:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313855, encodeId=1b8b13138559a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417475, encodeId=7945141e475fd, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508489, encodeId=1366150848980, content=<a href='/topic/show?id=7217e356711' target=_blank style='color:#2F92EE;'>#硫胺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73567, encryptionId=7217e356711, topicName=硫胺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87989977401, createdName=sjq030, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655527, encodeId=5d15165552e29, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 15 17:09:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198538, encodeId=6b2e1198538ae, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:22:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198537, encodeId=a310119853e1f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:21:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313855, encodeId=1b8b13138559a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417475, encodeId=7945141e475fd, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508489, encodeId=1366150848980, content=<a href='/topic/show?id=7217e356711' target=_blank style='color:#2F92EE;'>#硫胺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73567, encryptionId=7217e356711, topicName=硫胺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87989977401, createdName=sjq030, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-03-02 ms7000001770755343

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1655527, encodeId=5d15165552e29, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 15 17:09:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198538, encodeId=6b2e1198538ae, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:22:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198537, encodeId=a310119853e1f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:21:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313855, encodeId=1b8b13138559a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417475, encodeId=7945141e475fd, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508489, encodeId=1366150848980, content=<a href='/topic/show?id=7217e356711' target=_blank style='color:#2F92EE;'>#硫胺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73567, encryptionId=7217e356711, topicName=硫胺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87989977401, createdName=sjq030, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655527, encodeId=5d15165552e29, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 15 17:09:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198538, encodeId=6b2e1198538ae, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:22:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198537, encodeId=a310119853e1f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:21:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313855, encodeId=1b8b13138559a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417475, encodeId=7945141e475fd, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508489, encodeId=1366150848980, content=<a href='/topic/show?id=7217e356711' target=_blank style='color:#2F92EE;'>#硫胺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73567, encryptionId=7217e356711, topicName=硫胺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87989977401, createdName=sjq030, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1655527, encodeId=5d15165552e29, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 15 17:09:40 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198538, encodeId=6b2e1198538ae, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:22:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198537, encodeId=a310119853e1f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba675469410, createdName=ms7000001770755343, createdTime=Wed Mar 02 00:21:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313855, encodeId=1b8b13138559a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417475, encodeId=7945141e475fd, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508489, encodeId=1366150848980, content=<a href='/topic/show?id=7217e356711' target=_blank style='color:#2F92EE;'>#硫胺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73567, encryptionId=7217e356711, topicName=硫胺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87989977401, createdName=sjq030, createdTime=Tue Mar 01 12:09:40 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-03-01 sjq030

相关资讯

J Crit Care:血管加压素联合氢化可的松对休克患者血流动力学紊乱的影响

本研究的主要目的是评价对于难治性感染性休克发生短期血流动力学紊乱的患者,血管加压素(AVP)联合氢化可的松(HCT)治疗和其单独治疗疗效的影响。

NEJM:氢化可的松不能降低脓毒性休克者的死亡率

当前临床指南推荐,如果经过充足的液体复苏和升压药物治疗后,血流动力学仍不稳定的脓毒性休克患者可以给予氢化可的松治疗。但是该推荐意见基于低质量的证据,推荐水平也较弱。

NEJM:氢化可的松联合氟氢可的松降低脓毒性休克者的死亡率

脓毒性休克的特征为宿主对感染的反应失调,导致威胁生命的循环、细胞和代谢异常。短期死亡率为45-50%,50%的幸存者将遗留长期认知功能下降。对于脓毒症的治疗,目前仅推荐早期血流动力学管理、呼吸复苏以及给予适当的抗生素治疗,尚无被证明有效的额外治疗方案。最初的试验发现人类重组活化蛋白C和drotrecogin @(活化)对脓毒症的生存是有益的,但是未被随后的试验确认,这直接导致了Xigris(dro

JAMA Surg:帕瑞肽 vs氢化可的松用于;胰腺切除术并发症的预防

研究认为,对于预防胰腺手术后并发症,帕瑞肽的效果优于氢化可的松,特别是远端胰腺切除患者

JAMA:氢化可的松对重症新冠肺炎患者器官支持治疗天数的影响

对于需接受ICU治疗的重症新冠肺炎患者,接受氢化可的松治疗可减少患者接受器官支持治疗的天数

JAMA:皮质类固醇可提高COVID-19患者的生存率

皮质类固醇(Corticosteroids)是由肾上腺皮质制造和分泌的类固醇激素,也可经由人工合成。它的药理作用复杂,且广泛涉及生理系统作用,如压力反应、免疫反应,以及发炎、糖类代谢作用、蛋白质分解代

拓展阅读

儿童脓毒症评分系统(Phoenix Sepsis Score,PSS)

儿童脓毒症评分系统(Phoenix Sepsis Score,PSS)

【今日分享】2024年《儿童脓毒症和脓毒性休克的国际共识Phoenix标准》解读

现对儿童脓毒症现行标准的局限性、Phoenix儿童脓毒症新标准的制定、定义和与现行标准的比较、新标准的注意事项及局限性进行解读,供临床参考,以期提高儿科医师对脓毒症和脓毒性休克的规范诊断。限时免费分享

第八届东方会议引领行业风向标!探索重症治疗新境界,持续追踪速来围观!

本次会议,我们将围绕“提质强能促发展”这一主题展开深入探讨,希望通过各位专家学者的智慧和力量,进一步推动我国重症医学的发展。

JAMA:延长性与间歇性输注β-内酰胺类抗生素治疗成人脓毒症或脓毒性休克的比较:系统性评价与Meta分析

脓毒症和脓毒性休克的危重症患者具有较高的死亡率,β-内酰胺类抗生素是一线治疗抗生素。本研究通过系统性评价与Meta分析,评估延长性输注β-内酰胺类抗生素与间歇性输注相比,是否能够降低死亡风险。

ANESTHESIA & ANALGESIA:脓毒症患者出院后的生存率:一项队列研究

本研究发现,在重症监护室因脓毒症住院治疗的患者,出院后的死亡率与出院时的合并症和某些实验室测量值异常有关。

2023 ACR 适用性标准®脓毒症

美国放射学会(ACR,American College of Radiology) · 2023-08-15

2024更新—2016NICE指南:疑似脓毒症的识别,诊断和早期管理(NG.51)

英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence) · 2024-01-31

脓毒症诊断与治疗规范(T-CRHA 022-2023)

中国研究型医院学会(CRHA,Chinese Research Hospital Association) · 2023-10-02

Baidu
map
Baidu
map
Baidu
map